A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase
Real-world data shows asciminib improves molecular responses in chronic myeloid leukemia patients, suggesting better outcomes than traditional inhibitors.
Key Points
Patients treated with asciminib experienced fewer discontinuations than those on ATP-competitive inhibitors.
Asciminib users achieved deeper molecular responses, with higher rates of MR3 and MR4 compared to other therapies.
A retrospective chart review assessed real-world outcomes of asciminib in chronic myeloid leukemia patients.
Findings indicate that asciminib offers improved tolerability and efficacy as a second-line treatment.